Related Experiment Video
Updated: Aug 15, 2026
07:36
Intra-Omental Islet Transplantation Using h-Omental Matrix Islet filliNG (hOMING)
Published on: March 14, 2019
E1-INT (Transition Therapeutics/Novo Nordisk)
1La Jolla Institute for Allergy and Immunology, Department of Developmental Immunology, San Diego, CA 92121, USA. matthias@liai.org
Current Opinion in Investigational Drugs (London, England : 2000)
|November 2, 2005
Summary
E1-INT, an injectable islet neogenesis therapy, is being developed for type 1 and type 2 diabetes. This novel treatment combines growth factor and gastrin analogs and is currently in phase II clinical trials.
Area of Science:
- Endocrinology and metabolic diseases
- Regenerative medicine
- Pharmaceutical development
Background:
- Diabetes mellitus, a chronic metabolic disorder, affects millions globally.
- Current treatments primarily manage blood glucose but do not restore endogenous insulin production.
- Islet neogenesis offers a potential therapeutic strategy to regenerate pancreatic beta cells.
Purpose of the Study:
- To develop and evaluate E1-INT, an injectable islet neogenesis therapy.
- To assess the efficacy and safety of E1-INT in patients with type 1 and type 2 diabetes.
- To advance the treatment of diabetes through novel regenerative approaches.
Main Methods:
- E1-INT is an injectable therapy composed of an epidermal growth factor analog and a gastrin analog.
- The therapy aims to stimulate the formation of new insulin-producing islet cells.
- The compound is currently being investigated in phase II clinical trials.
Main Results:
- Phase II clinical trials are ongoing, with results pending.
- The therapy targets both insulin-dependent (type 1) and non-insulin-dependent (type 2) diabetes.
- Successful outcomes could indicate a significant advancement in diabetes treatment.
Conclusions:
- E1-INT represents a promising novel therapeutic candidate for diabetes.
- The ongoing clinical trials are crucial for determining the future of this islet neogenesis therapy.
- Further research and development are essential to address the unmet needs in diabetes management.
More Related Videos
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:02Prescription, Nonprescription and Orphan Drugs
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...